Prion diseases are characteristically accompanied by marked astrocytic activation, which is initiated relatively early in the disease process. Using the intracerebrally injected ME7 strain of prion agent to model disease, we identified an expected increase in GFAP (glial fibrillary acidic protein) but additionally noted an accumulation of GFAP cleavage fragments in hippocampal homogenates. A time-dependent increase in hippocampal µ-calpain immunoreactivity within astrocytes suggests that its proteolytic activity may account for the cleavage of GFAP that is observed in the ME7 model. It may therefore contribute to the reactive gliosis that is characteristic of prion diseases.
Introduction
Prion diseases are a group of neurodegenerative disorders known as the transmissible spongiform encephalopathies. They cause CNS (central nervous system) damage, characterized by vacuolation in the grey matter, reactive gliosis and neuronal cell death [1] . The disease is caused by the conformational change of the normal PrP c (cellular prion protein) into an aggregation-prone infectious form (PrP Sc ). PrP c is a membrane-bound glycoprotein, primarily located on the neuronal membrane, but is also found on other cell types such as astrocytes [2] . The intracerebral injection of the ME7 strain of prion agent provides a good in vivo model, in which gliosis is seen as early as 8 weeks post-infection. This gliosis coincides with the accumulation of PrP Sc within the hippocampus [3] . The exact role that microglia and astrocytes play in either the progression or inhibition of PrP Sc accumulation remains unresolved.
In the present study, we identified an expected increase in GFAP (glial fibrillary acidic protein) immunoreactivity during disease, but additionally identified the accumulation of GFAP fragments, consistent with proteolytic cleavage of the protein. Further immunohistochemical studies indicate that cleavage correlates with increased µ-calpain expression in astrocytes, consistent with previous observations in other models of CNS degeneration [4] [5] [6] .
Materials and methods

Tissue processing
All surgical procedures were carried out as detailed in [7] . Animals were given injections of normal or ME7-Key words: µ-calpain, central nervous system, glial fibrillary acidic protein, gliosis, ME7, prion disease. Abbreviations used: CNS, central nervous system; GFAP, glial fibrillary acidic protein; PrP c , cellular prion protein; PrP Sc , infectious form of PrP c . 1 To whom correspondence should be addressed (email bcg198@soton.ac.uk). infected brain homogenates and killed at 8, 12 and 21 weeks post-injection, to define early, medium and late stages of disease. Animals were terminally anaesthetized with sodium pentobarbital and perfused transcardially with heparinized saline. Brain tissue for immunohistochemistry (n = 5/time point) was further perfused with 10% neutral buffered formalin and paraffin-embedded. For Western blotting (n = 4/time point), the two lobes of the hippocampus were dissected out after heparin saline perfusion.
Protein homogenization and Western blotting
Hippocampi were solubilized in 2% (w/v) SDS solution with Complete TM protease inhibitor for 1 h to give a 10% (w/v) homogenate and centrifuged at 20 800 g. Equal amounts (10 µg) of total protein were resolved by SDS/PAGE and stained with colloidal Coomassie Blue or subjected to Western blotting using an anti-GFAP antibody (Dako; diluted at 1:5000). Protein band intensities were obtained by fluorescent imaging and normalized to total protein loading, as measured by Coomassie Blue staining. Significance (P < 0.05) was determined by ANOVA with post hoc pairwise comparisons using Holm-Sidak's multiple comparisons test.
Peptide mass 'fingerprinting'
The bands of interest from a colloidal Coomassie Blue-stained gel were excised and subjected to in situ trypsin digestion as described in [8] . The resulting peptides were separated by nano-reverse phase liquid chromatography using a Waters C18, 3 µm, 100 Å (1 Å = 0.1 nm) 150 mm × 75 µm (internal diameter) column and electrosprayed into a Global Ultima quadrupole TOF (time-of-flight) tandem mass spectrometer. Spectra were processed (ProteinLynx Global server 2.0) and searched against a FASTA format of the NCBI nonredundant database (June 2005). calculated from fluorescent labelling, normalized to total protein loading and plotted (**P < 0.01; ***P < 0.001). NBH, normal brain homogenate.
Immunohistochemistry
Paraffin-embedded coronal sections (10 µm) of the hippocampus were slide-mounted, dewaxed in xylene and rehydrated through a series of decreasing ethanol concentrations at room temperature (21
• C). Slides were immersed in a 65-80
• C preheated 0.2 M boric acid solution (pH 9) for 30 min and cooled to room temperature. Sections were washed in PBS and non-specific immunolabelling was blocked by incubation in the appropriate serum (10%) for 30 min. Sections were incubated with primary antibodies against either GFAP (Dako; diluted at 1:2000) or calpain-1 (Chemicon; diluted at 1:100) overnight at 4
• C. Sections were washed in PBS and incubated first with the appropriate biotinylated secondary antibody (Vector Laboratories, U.K.; diluted at 1:200) for 30 min and then with ABC (Vector Laboratories) for 30 min. Peroxidase was visualized using 0.02% diaminobenzidine and 1.5 mM ammonium nickel sulphate with 0.0 015% H 2 O 2 . 
Results and discussion
A comparison of control and ME7 hippocampal homogenates at 8, 12 and 21 weeks post-infection, by SDS/PAGE, showed the presence of an additional 45-48 kDa band in the 21-week ME7 samples ( Figure 1A ). Proteomic analysis identified the protein as astrocytic GFAP, which has a predicted molecular mass of 50 kDa. However, there was a notable absence of any signal from C-terminal peptide sequences, indicating that the lower-molecular-mass protein represents a proteolytic fragment of GFAP ( Figure 1B) . Indeed, Western blots of the same homogenate samples indicated a significant time-dependent increase in GFAP and a significant accumulation of fragments in end-stage disease ( Figure 1C) . The increased expression of GFAP is consistent with the astrocytic gliosis observed during disease as documented by immunohistochemistry (Figure 2A) .
Proteolytic cleavage of GFAP has been documented in other models of neurodegeneration, which show marked astrocytic gliosis combined with GFAP fragments of molecular masses ranging from 35 to 48 kDa [4] . Similar to our observations, increases in the amount of a 48 kDa GFAP fragment have been reported using astrocytic in vitro models of CNS injury [5, 6] . In these models, the influx of calcium via L-type voltage-sensitive calcium channels is thought to activate the calcium-dependent protease calpain. Indeed, calpain inhibitors are reported to block proteolysis and the resulting GFAP cleavage, and in addition to decrease reactive gliosis [5, 6] . Consistent with these reports, we show a similar increase in µ-calpain astrocytic immunoreactivity in latestage disease ( Figure 2B ). This implies that calpain is well placed to act on GFAP and drive its cleavage during disease progression.
Although gliosis and increases in GFAP immunoreactivity are characteristic events in prion disease, calpain activation has not been extensively studied within this model. However, our results build on previous observations from a number of neurodegenerative disease models in which calpain activation within microglia and astrocytes has been described [9, 10] . The precise significance of such observations in the prion model requires further investigation, but calpain activation may be linked to the presence of infectious PrP Sc . It has been suggested that accumulation of PrP Sc may occur initially within astrocytes, prior to any neuronal degeneration [11] . Indeed, it has been shown that the presence of PrP Sc causes an influx of calcium within astrocytes, specifically through L-type voltage-sensitive calcium channels [12] , and therefore calpain activation may be an indirect response to the accumulation of PrP Sc . Interestingly, calpain has been implicated in the endoproteolytic cleavage of PrP Sc into pathogenic C2 cleavage fragments [13] , the accumulation of which is prevented by calpain inhibitors. Taking these findings together, we hypothesize that the presence of PrP Sc alters the intracellular calcium concentration, initiating µ-calpain activation that in turn produces GFAP cleavage fragments. In addition, calpain may also aid in the propagation of pathogenic PrP Sc .
